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The 
 
Scurfy
 
 mutation of the 
 
FoxP3
 
 gene (
 
FoxP3
 
sf
 
) in the mouse and analogous mutations in 
human result in lethal autoimmunity. The mutation of 
 
FoxP3
 
 in the hematopoietic cells 
impairs the development of regulatory T cells. In addition, development of the Scurfy disease 
also may require mutation of the gene in nonhematopoietic cells. The T cell–extrinsic 
function of 
 
FoxP3
 
 has not been characterized. Here we show that the 
 
FoxP3
 
sf
 
 mutation leads 
to defective thymopoiesis, which is caused by inactivation of 
 
FoxP3
 
 in the thymic stromal 
cells. 
 
FoxP3
 
 mutation also results in overexpression of 
 
ErbB2
 
 in the thymic stroma, which 
may be involved in defective thymopoiesis. Our data reveal a novel T cell–extrinsic function 
of 
 
FoxP3
 
. In combination, the T cell–intrinsic and –extrinsic defects provide plausible 
explanation for the severity of the autoimmune diseases in the scurfy mice and in patients 
who have immunodysregulation, polyendocrinopathy, enteropathy, and X-linked syndrome.
 
A long-standing, but poorly understood, paradox
in immunology is the link between defective
T cell production in the thymus and T cell–
dependent autoimmune diseases. Thus, in the
human, DiGeorge syndrome can lead to au-
toimmune diseases (1–5); thymoma is commonly
associated with myasthenia gravis (6, 7), whereas
thymic hypoplasia is associated with autoimmune
hemolytic anemia and juvenile pemphigoid (8).
The diabetes-prone BB rats have severe defects
in thymocyte development because of muta-
tions of the 
 
IAN
 
 gene family members (9, 10).
Mutations of the 
 
FoxP3
 
 gene are responsible
for the spontaneous autoimmune diseases that
are observed in patients who have immunodys-
regulation, polyendocrinopathy, enteropathy,
X-linked syndrome (IPEX) and scurfy mice
(11–14). Studies have revealed that 
 
FoxP3
 
 gene
expression in CD4 lymphocytes is essential for
the development and function of CD4
 
 
 
CD25
 
 
 
regulatory T cells (T reg cells) (15–17). How-
ever, several lines of evidence also suggest that
defective T reg cell development alone may be
insufficient to initiate such severe autoimmune
diseases as those observed in scurfy mice and
IPEX patients. Thus, irradiation chimeras using
bone marrow from scurfy mice demonstrated
that the defective 
 
FoxP3
 
 expression in the he-
matopoietic cells did not lead to the develop-
ment of autoimmune disease (18). Second,
transgenic expression of WT 
 
FoxP3
 
 under the
 
lck
 
 promoter did not rescue the autoimmunity
in scurfy mice, although it is unclear whether
modest elevation of the 
 
FoxP3
 
 gene in the
spleen of one founder line can restore T reg
cell function fully (19).
T lymphocytes are produced in the thymus
through an ordered process. Upon their arrival
in the thymus, T cell precursors divide rapidly
before their expression of the CD4 and CD8
coreceptors on the cell surface (20). Based on
the cell surface expression of CD44 and CD25
markers, the development of double negative
(DN) thymocytes can be divided into 4 stages
(21). DN1 expresses CD44, but not CD25.
With the expression of CD25, the DN1 T
cells enter into the DN2, which expresses
CD25 and CD44, and actively divide. The
DN2 cells diminish the expression of CD44
and enter into the DN3 stage. With the rear-
rangement of the TCR
 
 
 
 gene, the DN3 cells
enter into the second and most active wave of
division and maturate into DN4 cells, which
are characterized by down-regulation of CD25.
The DN4 T cells are the direct precursors of
CD4
 
 
 
CD8
 
 
 
 immature single positive T cells
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(22), which are believed to differentiate into CD4
 
 
 
CD8
 
 
 
 T
cells that express functional TCR
 
  
 
 genes and undergo
TCR ligand-based positive and negative selection (23). Only
the T cells that succeed in both selections are allowed to ma-
ture and populate the peripheral lymphoid organs. Despite
the clear delineation of the developmental pathway, the mo-
lecular mechanisms by which the thymic epithelial cells con-
trol thymopoiesis remains poorly understood.
Here we report that the 
 
Scurfy
 
 mutation of 
 
FoxP3
 
 leads
to thymic atrophy, which is mainly the result of the dimin-
ished DN thymocyte proliferation. This phenomenon is due
to the 
 
FoxP3
 
 mutation in the nonhematopoietic lineages.
Furthermore, defective thymopoiesis correlates with overex-
pression of 
 
ErbB2
 
 in the thymic stroma, an event that is
known to cause the thymic atrophy (24). 
 
FoxP3
 
 represses
expression of the 
 
ErbB2
 
 gene in a thymic epithelial cell line.
These results reveal a novel T cell–extrinsic role of 
 
FoxP3
 
 in
stromal cells for the development of T cells.
 
RESULTS
Defective thymopoiesis rather than accelerated death 
of thymocytes leads to reduced thymic cellularity of 
 
FoxP3
 
sf
 
 mice
 
The hemizygous 
 
FoxP3
 
sf
 
 male mice usually dies between
18–25 d of age (unpublished data). We examined the mice at
1 or 2 wk of age, and found that thymii of the mutant mice
were atrophic. The number of thymocytes in the 
 
FoxP3
 
sf
 
mice was reduced by twofold on day 7 and by about three-
fold on day 15 (Fig. 1 a). On day 7, the major thymocyte
subsets were present, although a small reduction of double
positive (DP) thymocytes was found. Corresponding to this,
the percentages of CD4
 
 
 
CD8
 
 
 
, CD4
 
 
 
CD8
 
 
 
, and CD4
 
 
 
CD8
 
 
 
 populations were increased when compared with
normal littermates (Fig. 1 b). Because the thymic cellularity
was reduced by about threefold, there was no increase in the
number of mature T cells in the thymus.
Proliferation and apoptosis shape thymic cellularity (25).
To explore the possible contributions of apoptosis, flow cy-
tometric analysis of Annexin V
 
 
 
 cells was performed on ex
vivo thymocytes that were isolated from mice on days 7 and
15 after birth (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20050157/DC1). The percentage of An-
nexin V
 
 
 
 thymocytes in scurfy mice was comparable to that
in WT littermates. These data indicate that thymic atrophy
in the 
 
FoxP3
 
sf
 
 mice probably is not due
 
 
 
to increased apopto-
sis of the thymocytes.
We then examined the proliferation of thymocytes in
 
FoxP3
 
sf
 
 mice. Scurfy mice and their littermates were injected
with nucleotide analogue bromodeoxyuridine (BrdU) at 3 h
before sacrifice, and BrdU incorporation was measured by
flow cytometry after surface staining for CD4 and CD8 ex-
pression and intracellular staining for BrdU incorporation.
As shown in Fig. 1 (c and d), the percentage of BrdU
 
 
 
 thy-
mocytes was substantially lower in 
 
FoxP3
 
sf
 
 mice than that in
normal littermates. Analysis of thymocyte subsets revealed
that BrdU incorporation was reduced significantly in
CD4
 
 
 
CD8
 
 
 
 DP (day 15 only), CD4
 
 
 
CD8
 
 
 
 DN, and single
positive (SP) CD4
 
 
 
CD8
 
 
 
 
 
thymocytes (Fig. 1, d and e).
Consistent with the previous report, most of the BrdU-
labeled CD8 SP T cells in WT mice had no or lower levels
of cell surface CD3/TCR (22). The division of this imma-
ture subset was repressed significantly in the 
 
FoxP3
 
sf
 
 mice. In
contrast, only a minor reduction was observed among the
more mature SP cells with high levels of TCR, regardless of
whether they were CD4
 
 
 
SP or CD8
 
 
 
SP (Fig. 1, d and e).
Thus, the 
 
FoxP3
 
sf
 
 mice have significant defects in the prolif-
eration of immature T cells.
DN thymocytes differentiate sequentially through the
DN1 (CD25
 
 
 
CD44
 
 
 
), DN2 (CD25
 
 
 
CD44
 
 
 
), DN3
(CD25
 
 
 
CD44
 
 
 
), and DN4 (CD25
 
 
 
CD44
 
 
 
) subsets; the
proliferation of DN thymocytes is most prominent in the
DN2 and DN4 stages. The most significant reduction of
BrdU incorporation was observed in the DN4 stage, al-
though DN2 thymocytes in the 
 
FoxP3
 
sf
 
 mice also had less
proliferation (Fig. 1, f and g). Proliferation of the DN1 and
DN3 thymocytes was not reduced significantly. Moreover,
compared with WT littermates, the distribution of DN sub-
sets also was altered greatly in the mutant mice. In the 
 
FoxP3
 
sf
 
mice, the DN1 population was expanded, whereas the DN4
population was reduced significantly (Fig. 1 h). In addition,
consistent with the reduced proliferation, the size of the DN4
thymocytes from the 
 
FoxP3
 
sf
 
 mice was significantly smaller
than those from WT mice (Fig. 1 i). Together, our results re-
vealed that defective proliferation of immature thymocytes is
responsible for thymic atrophy in the 
 
FoxP3
 
sf
 
 mice.
 
Reduced thymopoiesis in the 
 
FoxP3
 
sf
 
 mice is independent of 
T cell activation in the periphery and is extrinsic to bone 
marrow–derived cells
 
Because the 
 
FoxP3
 
sf
 
 mice have ongoing T cell activation in
the periphery, it is possible that such activation can affect thy-
mopoiesis indirectly. To address this issue, we produced 
 
Rag-
2
 
 
 
/
 
 
 
FoxP3
 
sf
 
 mice. 
 
Rag-2
 
 
 
/
 
 
 
FoxP3
 
wt
 
 mice expressed low, but
detectable levels, of 
 
FoxP3
 
 mRNA, and perhaps because of
RNA instability that is associated with the frame-shift muta-
tion, the mutant 
 
FoxP3
 
sf
 
 mice have further reduced levels of
 
FoxP3
 
 mRNA (Fig. 2, a and b). Because 
 
Rag
 
 deficiency ar-
rests thymocyte development at the DN3 stage, one can study
the effect of the mutations on thymocyte development up to
the DN3 stage in the absence of peripheral T cell activation.
The thymocyte subsets (Fig. 2, c and d) and BrdU incorpora-
tion (Fig. 2, e and f) were altered significantly in the 
 
Rag-2
 
 
 
/
 
 
FoxP3sf mice in comparison with the Rag-2 /  mice. The al-
terations in the DN1–3 subsets were similar to what were
found in Rag-2 / FoxP3sf mice, particularly the expansion of
DN1 thymocytes. Thus, the changes in the DN1–3 stages and
diminished proliferation of DN thymocytes were indepen-
dent of T cell activation in the periphery.
To study the impact of the FoxP3 mutation in the stroma
cells on the development of DN thymocytes, we transferredJEM VOL. 202, October 17, 2005 1143
ARTICLE
bone marrow from BALB/c transgenic mice that express
GFP into sublethally irradiated Rag-2 /  or Rag-2 / FoxP3sf
mice. 6 wk after the transfer, we analyzed the proliferation
and the development of GFP  thymocytes. As demonstrated
in Fig. 3 a, the CD4- and CD8-expressing thymocytes that
developed with FoxP3sf stroma were normal compared with
Figure 1. Abnormal thymopoiesis in the FoxP3sf mice. (a) Progressive 
reduction of thymic cellularity in the BALB/c. FoxP3sf mice. Numbers represent 
the mean cell number   SEM per thymus. The number of mice examined: day 
7–9, FoxP3sf n   5, WT n  8; day15–18, FoxP3sf n  10, WT n   12. (b) Thy-
mocyte subsets based on expression of CD4 and CD8 markers. Thymii were 
isolated on days 7–9 or days 15–18 after birth, and analyzed by flow cytome-
try. Data shown are representative profiles of day-15 mice. (c) Proliferation of 
thymocyte subsets. Representative line graphs of thymocytes and their sub-
populations of mice at day 15. The numbers represent the percentages of 
BrdU  cells in each subpopulation. Mice at day 7 or 15 of age were injected i.p. 
with BrdU (1 mg/mouse) 3 h before sacrifice. Thymocytes were stained with 
PE– or PerCP–Cy5.5-conjugated anti–mouse CD4 and allophycocyanin-
conjugated anti-mouse CD8 mAbs, then intracellularly with FITC-conjugated 
anti-BrdU antibody, and were analyzed by flow cytometry. (d) Summary of 
BrdU incorporation data of major thymocyte subsets. Data shown are mean 
percentages   SEM. The top panel shows the data from 7-d-old mice (FoxP3sf 
mice, n   5; WT littermates n   7); the bottom panel depicts the data of 
15-d-old mice (FoxP3sf mice, n  10; normal littermates, n   12). (e) As in (d), 
except that the CD8 CD4  thymocytes were divided into CD3  and CD3  
subsets. (f) BrdU incorporation of DN thymocytes at four stages. DN1: 
CD44 CD25 ; DN2: CD44 CD25 ; DN3: CD44 CD25 ; DN4: CD44 CD25 . 
(g) Summary of BrdU  percentage among DN1–4. Data represent mean   
SEM (FoxP3sf mice, n   10; WT, n 12). (h) FACS profiles of DN thymocytes 
of 15-d-old FoxP3sf mice. Thymocytes from FoxP3sf or WT littermates were 
stained by CD4, CD8, CD25, and CD44. The DN thymocytes were divided based 
on expression of CD44 and CD25. (i) Cell size of the mutant thymocytes at 
different DN stages compared with WT littermates, as indicatd by their for-
ward scatters (FCS). Data are representative of four independent experiments.T CELL EXTRINSIC FUNCTION OF FOXP3 GENE IN THYMOPOIESIS | Chang et al. 1144
FoxP3wt stroma. However, analysis of DN thymocytes by
CD25 and CD44 markers revealed significant increases in
DN2 and DN3, and a significant reduction in DN4 (Fig. 3,
b and c). In addition, proliferation of DN thymocytes also
was reduced in the mutant recipients. In two independent
experiments, the BrdU incorporation was lower in the Rag-
2 / FoxP3sf mice as compared with their Rag-2 / FoxP3wt
littermates. Although the baseline proliferation was different
in the two experiments, perhaps as a result of the age of
recipients and the time of analysis, the reduction was sta-
tistically significant (P   0.019) in a pair-wise comparison
between WT and mutant siblings (Fig. 3, d and e). Further-
more, in the mutant recipient, DN2 and DN4 thymocytes
also had reduced blasting cells compared with the WT recip-
ient (Fig. 3 f). These results demonstrate that the mutation of
FoxP3 in the thymic stroma cells is sufficient to cause defec-
tive DN thymocyte development.
To test whether FoxP3 mutation in the bone marrow cells
also contributes to defective thymopoiesis, we transferred T
cell–depleted bone marrow from Thy1.1  WT or Thy1.1
FoxP3sf BALB/c mice into separate Rag-2 /  recipients,
which received 500 rad of  -irradiation before reconstitution.
At 10 wk after reconstitution, the chimera mice were killed
and analyzed. At this point,  95% of thymocytes and spleen
Figure 2. Abnormal thymopoiesis in the FoxP3sf Rag2    mice. 
(a and b) Expression of the FoxP3 gene in the BALB/c. Rag-2 /  and BALB/c. 
Rag-2 / FoxP3sf thymus, as determined by real-time PCR. A typical PCR 
profile is shown in (a); the summary data, including three mice per group, 
is shown in (b). Each sample was analyzed in triplicate. (c–f) The impact of 
FoxP3 mutation on the DN development. 5-wk-old BALB/c.Rag2 /  FoxP3sf 
mice received an injection of BrdU (1 mg/mouse) 6 h before sacrifice. 
(c) FACS profiles of the thymocytes from FoxP3sf Rag2  /  or FoxP3wt 
Rag2 /  recipients. (d) BrdU incorporation at different stages. Data are 
representative of two independent experiments involving three Rag2 /  
FoxP3sf mice and five Rag 2 /  FoxP3wt mice. Representative profile (e) and 
summary (f) of BrdU incorporation data from two independent experi-
ments involving three mutant and five WT mice.JEM VOL. 202, October 17, 2005 1145
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cells were of donor origin (unpublished data). The number of
thymocytes in the mice that received FoxP3sf bone marrow
was comparable to that in the mice that received WT bone
marrow (unpublished data). The distribution of thymocyte
subsets as revealed by CD4 and CD8 markers also was unaf-
fected. More importantly, no appreciable effect was observed
in the DN1–DN4 subsets and BrdU incorporation. Thus,
proliferation and the development of DN thymocytes were
unaffected (Fig. 4 a). Therefore, defective FoxP3 expression in
hematopoietic lineages is not sufficient to cause defective thy-
mopoiesis. In the periphery, an increased number of T cells
were found in the spleen and lymph nodes of mice that were
reconstituted with mutant bone marrow (unpublished data).
However, the activation status and rate of proliferation were
comparable between the two types of chimeras (Fig. 4 b).
Consistent with previous observations (18), all of the
chimera consisting of mutant bone marrow and irradiated
WT host survived significantly longer than did the mutant
scurfy mice (Fig. 5). When killed for analysis at 8–10 wk, the
healthy mice showed increased cellularity in the lymph
nodes (not depicted), although we did not observe increased
activation markers on the T cells in these chimeras (Fig. 4 b).
In the C57BL/6 background, all eight chimeras survived the
entire period of observation (Fig. 5 a). In the BALB/c back-
ground—except for those mice that were killed for analy-
sis—recipients of FoxP3sf bone marrow succumbed between
8 and 20 wk after transplantation (Fig. 5 b). The difference
in survival between these two strains is unclear. However,
analysis of moribund mice revealed extremely small thymii
and reduced cellularity in the peripheral lymphoid organs.
Figure 3. FoxP3 defect in thymic stroma cells leads to defective 
thymopoiesis. 5   106 T cell–depleted bone marrow cells from GFP trans-
genic mice were transferred into 3- or 4-wk-old Rag-2 / FoxP3sf mice or 
Rag-2 /  FoxP3wt littermates, which received sublethal irradiation (500 rad) 
1 d before transplantation. 5 or 6 wk after the transplantation, the donor 
thymocytes were gated based on GFP expression. Thymocyte subsets 
based on expression of CD4/CD8 (a), and DN subsets based on CD25/CD44 
markers (b). Representative FACS profiles (a and b) and summary data from 
two independent experiments (c) are shown. (d and e) BrdU incorporation of 
DN of donor (GFP ) origin. Representative FACS profile (d) and summary 
data (e) from two independent experiments are presented. In experiment 1 
(open symbols), the recipients are 4-wk-old at the time of reconstitution, 
and were analyzed at 6 wk after reconstitution; in experiment 2 (solid 
symbols), the recipients were 3-wk-old at the time of reconstitution, and 
were analyzed 5 wk later. The two-related sample Wilcoxon test was used 
to examine the statistical significance of the difference between WT and 
mutant littermate recipients. (f) Cell size of GFP  DN thymocytes at differ-
ent stages. All data have been repeated in 2 independent experiments 
involving 3 FoxP3sf Rag-2 /  and 5 FoxP3wt Rag-2 /  mice.T CELL EXTRINSIC FUNCTION OF FOXP3 GENE IN THYMOPOIESIS | Chang et al. 1146
Thus, these moribund mice did not have the typical patho-
logic changes that are observed in the scurfy mice (i.e., in-
creased lymph proliferation). However, the T cells in the
moribund mice were highly activated. Because bone mar-
row did contain a small number of T cells, it is unclear
whether the pathogenic T cells were generated in the scurfy
donor or in the WT recipients. Because the delay and/or ab-
lation of diseases cannot be accounted for by the 3–4 wk that
is required for the generation of T cells in chimera mice to
the level seen in newborn mice, it seems that the Scurfy mu-
tation of FoxP3 in the hematopoietic cells did not result in
the full spectrum of polyclonal T cell activation and patho-
genicity that is typical of scurfy mice (26).
Together, these data demonstrate that the FoxP3sf defects
in nonhematopoietic tissues are necessary and sufficient for
reduced thymopoiesis. In contrast, the defects in bone mar-
row–derived cells are neither necessary nor sufficient for the
thymopoietic defects that are described herein. The signifi-
cant delay in onset and incidence of autoimmune diseases in
the chimera mice are consistent with the notion that muta-
tion of FoxP3 in the non-T host cells may be essential for
the development of autoimmune diseases. At the least, the T
cell–extrinsic defects help to exacerbate autoimmune diseases
in the scurfy mice.
Expression of the FoxP3 gene in the thymic epithelial cells
We have shown that a defective FoxP3 gene in nonhemato-
poietic thymic cells mediated thymopoiesis defects. This
suggests that FoxP3 must be expressed in some types of thy-
mic stromal cells. We took two approaches to detect FoxP3
expression in the thymic stromal cells. First, we separated
thymocytes into CD45  and CD45  compartments by
MACS beads. The thymic epithelial cells were isolated from
the CD45  compartment based on their binding to mono-
clonal antibody G8.8 (27) (Fig. 6 a). After two rounds of
FACS sorting of the CD45 G8.8  epithelial cells to near
100% purity, expression of FoxP3 in the CD45  thymocytes
and the CD45 G8.8  thymic epithelial cells was quantitated
by real-time PCR. As shown in Fig. 6 b, the highly purified
CD45 G8.8  cells have  2–20-fold more FoxP3 mRNA
compared with CD45  cells, depending on the housekeep-
ing genes used. The FoxP3 mRNA was not due to T cell
contamination, because the expression of the CD3  chain
was barely detectable in the epithelial population.
To locate the expression pattern of FoxP3 protein in var-
ious types of cells in the thymus, we produced affinity-puri-
fied rabbit anti-FoxP3 antibodies (Fig. S2, available at http:
//www.jem.org/cgi/content/full/jem.20050157/DC1). To
determine whether FoxP3 was present in the thymic epithe-
lial cells, we costained FoxP3 with cortical epithelial cell
marker K8 and/or medullar epithelial K5. A small, but con-
siderable, number of epithelial cells in the cortex (Fig. 6 c),
but not in the medulla, expressed FoxP3 protein. The speci-
ficity of the staining was confirmed, because the thymus
from the FoxP3sf mice was negative for FoxP3 protein. In
contrast, no K5 FoxP3  cells were found in the medulla
(unpublished data). The immunohistochemical data were
corroborated by flow cytometry using a monoclonal anti-
FoxP3 antibody (Fig. 6 d). Mouse thymic epithelial cells also
expressed significant levels of CD4 mRNA (Fig. 6 b) and
protein (Fig. 6 d). Thus, in addition to its expression in the
lymphocyte lineages as others have reported, FoxP3 was de-
tected in CD45  stromal cells, with high levels found among
a small number of cortical epithelial cells. This expression
pattern is consistent with the effect of FoxP3 mutation on
the development of immature thymocytes that reside pri-
marily in the cortex.
FoxP3 suppresses expression of ErbB2
Abnormal expressions of several molecules affect thy-
mopoiesis, including overexpression of ErbB2 (24) and tar-
geted mutation of IL-7 (28). As shown in Fig. 7 a, no signif-
icant difference in IL-7 expression was observed in 7- and
15-d-old FoxP3sf thymii when compared with thymii from
WT littermates. In contrast, expression of ErbB2 mRNA
was elevated significantly in thymii of the FoxP3sf mice, as
Figure 4. Normal thymopoiesis of WT and FoxP3sf bone marrow 
reconstituted Rag-2    mice. T cell–depleted bone marrow cells from 
Thy1.1 FoxP3sf mice or WT littermates were transferred into sublethally 
(500 rad) irradiated Thy1.2 Rag-2 /  mice. 10 wk after the transfer, 
thymocytes were harvested and their cellularity, proliferation, and sub-
set distribution were analyzed. (a) Subsets of total thymocytes (top), DN 
(middle), and BrdU incorporation of DN thymocytes (bottom) over a 3-h 
period. (b) Activation and proliferation of spleen T cells. Top, distribution of 
CD4 and CD8 T cells subsets. Note the increase in the proportion of T cells 
when bone marrow is from the FoxP3sf mice. Middle, activation status as 
revealed by CD44 and CD62L. Bottom, incorporation of BrdU over a 3-h 
period. Data shown are profiles of Thy1.1  cells, which account for  95% 
of spleen T cells and thymocytes, and are from a representative mouse in 
an experiment involving two mice per group. Essentially identical results 
were obtained when C57BL/6.FoxP3sf bone marrow cells were used to recon-
stitute the irradiated C57BL/6.Rag-1 /  mice and when BALB/cFoxP3sfOtcspf 
mice bone marrow was used to reconstitute the BALB/cRag-2 /  mice.JEM VOL. 202, October 17, 2005 1147
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revealed by real-time PCR (Fig. 7 b). To determine
whether  FoxP3 can suppress the expression of the ErbB2
gene in the thymic epithelial cells, we transfected the thymic
epithelial cell lines 6.1.7 with FoxP3 cDNA, and analyzed
ErbB2 expression 3 d after transfection. We found that the
ErbB2 expression level in the 6.1.7 cells was reduced by five-
fold with the ectopic expression of FoxP3 (Fig. 7 c). Thus,
the FoxP3 expression in the thymus epithelial cell line di-
rectly suppresses expression of the ErbB2 gene. To deter-
mine whether FoxP3 represses ErbB2 promoter activity, we
cloned the 500-bp ErbB2 promoter (29–31) into a pGL-2
luciferase reporter vector, and transiently transfected the re-
porter, in conjunction with FoxP3 or vector control, into
6.1.7. As shown in Fig. 7 d, FoxP3 cDNA repressed the
ErbB2 promoter activity by two- to fivefold in a dose-
dependent manner.
DISCUSSION
FoxP3 is a major regulator for the development and function
of CD25 CD4  T reg cells (15–17). This function requires
expression of FoxP3 in the T cell lineages. Although the
Scurfy mutation in the non-T cells seems to be necessary for
the pathogenesis of the disease in the mice (18), the immu-
nologic basis for a T cell–extrinsic function of FoxP3 has not
been identified. We show here that the FoxP3 mutation re-
sult in significantly reduced thymic cellularity. This reduc-
tion is due to defective proliferation of immature T cells,
which is caused by FoxP3 defects in the thymic stroma, but
not in the T cells. Our systematic analysis of the proliferation
of thymocyte subsets revealed that FoxP3 mutation primarily
affects proliferation of immature T cells, including those of
DN2 and DN4, the major stages of thymocyte proliferation,
and to a less extent, immature single positive and DP thy-
mocytes. In addition, increased apoptosis of thymocytes did
not seem to contribute to reduced thymic cellularity, at least
at early ages ( 2 wk). This is very different from the re-
duced thymic cellularity that is associated with peripheral T
cell activation, which can cause the nonspecific deletion of
DP thymocytes (32). Consistent with these findings, the thy-
mic abnormalities that we observed in the scurfy mice have
not been reported in other lymphoproliferative disease mod-
els, such as CTLA4 KO mice (33–35). Moreover, analysis of
Rag-2 / FoxP3sf mice demonstrated that the defects in the
DN1–DN3 thymocytes cannot be due to peripheral T cell
activation. In addition, in chimera mice that were reconsti-
tuted with WT bone marrow cells, generation of DN4 and
proliferation of DN thymocytes was compromised in the
FoxP3sfRAG-2 /  host. To our knowledge, this is the first
direct demonstration of FoxP3 function in overall T cell de-
velopment, and is a direct link between FoxP3 expressed in
thymic stromal cells and the proliferation of immature T
cells. In addition to their diminished proliferation, we also
found the subset distribution of the DN thymocytes was af-
fected significantly by FoxP3 mutation. This is characterized
by the increased DN1 and reduced DN4 populations. How-
ever, both changes can be explained by defective prolifera-
tion at DN2 and DN4.
An important question is whether the defective thy-
mopoiesis in the mutant mice contributes to the pathogene-
sis of disease in the scurfy mice and patients who have IPEX.
Theoretically, reduced production of new T cells may stim-
ulate lymphoproliferation that is characteristic of the scurfy
mice, although additional studies are needed to establish such
a link. It remains controversial whether mutation of FoxP3
in the T cell lineage is necessary and sufficient to cause lethal
autoimmune diseases. More than 10 yr ago, it was demon-
strated that adoptive transfer of bone marrow cells from
nude scurfy mice into SCID mice or irradiated syngeneic
Figure 5. Bone marrow cells from the FoxP3sf mice either fail or 
have diminished ability to transfer autoimmune diseases to the Rag-
deficient syngeneic host. Data shown are the survival of scurfy mice or 
syngeneic Rag-deficient mice that received bone marrow cells from the 
scurfy mice in C57BL/6 (a) or BALB/c (b) background. Kaplan-Meier analyses 
were used to compare the two groups. P values of the log rank test are 
presented. One accidental death at 3 wk in the BALB/c group was excluded 
from the analysis. Some mice have not been observed throughout the 
experiments because the experiments are ongoing or because they were 
used to analyze T cell development. These samples were marked as censored 
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mice failed to transfer autoimmune diseases (18, 36, 37).
Likewise, we have observed substantial survival irradiation
chimera of the Rag-deficient mice that were reconstituted
with  FoxP3sf bone marrow. Conversely, recent work by
Fontenot et al. (38) demonstrated that when CD4 pro-
moter–driven  Cre induced deletion of FoxP3 in the
FoxP3flox/flox in transgenic mice, they developed the full spec-
trum of Scurfy disease. However, although Cre under the
CD4 promoter induced gene deletion in the T cell lineage,
its impact on the thymic epithelial cells has not been studied.
Our data demonstrate that the CD4 gene is expressed in
mouse thymic epithelial cells.
Finally, although the FoxP3 gene has features of tran-
scription factors, its down-stream targets have not been
identified. Our data reveal ErbB2 as one of its molecular tar-
gets, because the ErbB2 gene is overexpressed in the thymic
stromal cells. Conversely, transfection of FoxP3 represses ex-
pression of ErbB2 in the thymic epithelial cell lines, at least
in part, by transcriptional repression. Our results are consis-
tent with two previous studies that support a critical role for
ErbB2 in thymopoiesis. First, transgenic expression of ErbB2
under the keratin promoter, which resulted in overexpres-
sion of HER-2 in skin and thymic epithelial cells, leads to
thymic atrophy (24). Therefore, overexpression of ErbB2, as
a result of FoxP3 mutation, may contribute to thymic atro-
phy. Second, a recent study revealed that mice with targeted
mutation of the Stat-3 gene also showed reduced thy-
mopoiesis, increased ErbB2 expression, and thymic atrophy
(39). Our studies with cross-reactive anti–HER-2 antibodies
indicated that overexpression of ErbB2 contributed to de-
fective thymopoiesis (Fig. S3, available at http://www.jem.
org/cgi/content/full/jem.20050157/DC1).
Taken together, our results reveal the first non-T cell in-
trinsic function of FoxP3; it serves as a novel checkpoint for
Figure 6. FoxP3 expression in thymic epithelial cells. Thymii from 
4–6-wk-old WT mice were digested with Collagenase/Dispase to prepare 
single-cell suspensions. The cells were stained with anti–CD45.2-PE and 
unlabeled G8.8. The CD45  cells (99% pure) were isolated with anti–PE-MACS 
beads. After extensive depletion of MACS  cells, we added FITC-conjugated 
anti–rat IgG2a to the CD45  population. The CD45 G8.8  cells were sorted 
twice using the FACS Vantage. (a) FACS profiles that show expression of 
CD45 and G8.8 of total cell preparation (upper left), purified CD45  cells 
(lower left), remaining cells after depletion of CD45  cells (upper right), and 
the sorted CD45 G8.8  epithelial cells (lower right). (b) FoxP3 and CD4 
expression in the thymic epithelial cells (CD45–G8.8 ) compared with the 
CD45  population as measured by real-time PCR. To normalize the cell 
numbers, the ratios of FoxP3 or CD4 mRNA and that of housekeeping gene 
Hprt or  -actin are presented. Expression of the CD3  chain was used to mark 
potential T cell contamination. Data shown are means and SEM of triplicates 
from two independent experiments. (c) Immunofluorescence staining of the 
thymus sections for cortical epithelial marker Cytokeretin 8 (K8, left panels) 
and for FoxP3 protein (as determined by rhodamine-conjugated goat anti–
rabbit IgG, middle panels); merged images are presented in the right panels. 
The cortex regions are shown. Medulla epithelial cells show no FoxP3 staining 
(not depicted). Top panels are specificity controls that show an absence of 
FoxP3 protein in the thymus of FoxP3sf mice. Lower panels show 40  image 
of the area boxed in the middle panels. The K8 FoxP3  cells are indicated by 
arrows. (d) Expression of FoxP3 and CD4 in thymic epithelial cells as revealed 
by flow cytometry. Lower panels show the staining profile of CD45 and 
G8.8; thymic epithelial cells are defined in the CD45 G8.8 gate. The upper 
panels show line graphs depicting the distribution of CD4 or Foxp3 expression 
(solid lines). Isotype controls (iso) are shown as dotted lines. The circles in 
the bottom panels show gates of epithelial cells. Data are representative of 
two or three independent experiments.JEM VOL. 202, October 17, 2005 1149
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thymopoiesis. Combined T cell–intrinsic and –extrinsic defects
provide a plausible explanation for the severity of autoimmune
diseases in the scurfy mice and patients who have IPEX.
MATERIALS AND METHODS
Animals. Thy1.1 BALB/c mice with mutation of FoxP3 (FoxP3sf) were
produced after more than 12 generations of backcross in the University of
North Carolina. They were maintained under specific pathogen-free condi-
tions at the University Laboratory Animal Resources at the Ohio State Uni-
versity for the duration of the study. Male Rag-2 /  FoxP3sf mice were gen-
erated by breeding female FoxP3sf/  heterozygous BALB/c mice with male
Rag-2 /  mice. The genotype of the FoxP3 gene was determined by allele-
specific PCR (11). Primers specific for mutant FoxP3 gene include forward
primer (5 -TCAGGCCTCAATGGACAAAAG-3 ), reverse primer (5 -
AACTATTGCCATGGCTTCC-3 ) and complementary depository oli-
gonucleotides (5 -CTTGTCCATTGAGGCTGAG-3 ). The primers spe-
cific for the WT FoxP3 gene were forward primer (5 -CTCAGGCCT-
CAATGGACAAG-3 ), reverse (5 -AACTATTGCCATGGCTTCC-3 )
and complementary depository oligonucleotides (5 -CTTTTGRCCAT-
TGAGGC-3 ). The complementary depository oligonucleotides were used
to improve the reliability of allele-specific PCR (40). Male FoxP3sf or
FoxP3sfOtcspf mice and normal gender-matched littermates were used in
some experiments. Animal studies were approved by the Institutional Re-
view Board of the Ohio State University.
Thymocyte apoptosis. Cell viability of thymocyte subsets was deter-
mined by flow cytometry with PE-conjugated anti–mouse CD4 and allo-
phycocyanin (APC)-conjugated anti–mouse CD8 mAbs, and then FITC-
conjugated Annexin V. Apoptotic cells were identified as Annexin V .
BrdU incorporation and measurement. Mice were injected i.p. with
nucleotide analog bromodeoxyuridine (BrdU; 1 mg/mouse in 100  l PBS)
3 h before sacrifice, except where indicated. The mice were killed, and sin-
gle thymocytes and spleen cells were prepared. BrdU incorporation was de-
tected by flow cytometry with a BrdU Flow Kit, as described by the manu-
facturer (BD Biosciences). In brief, thymocytes or spleen cells were stained
with various surface markers, then the cells were fixed, treated with DNase
(Sigma-Aldrich), and stained with FITC-conjugated or APC-conjugated
anti-BrdU mAb (clone 3D4) or FITC-conjugated mouse IgG1.
Bone marrow chimera. For the bone marrow reconstitution, 6–8-wk-
old Rag2 /  BALB/c mice received 500 rad of  -irradiation 1 d before
transplantation. Bone marrow cells from FoxP3sf or the WT littermates
were purified, and T cells were depleted using anti-CD4 (GK1.5) and anti-
CD8 (2.4.3) antibodies followed by DYNAL Beads (Dynal) as described by
manufacturer. After the deletion, the CD3  cells within the bone marrow
were always  2%. 8   106 bone marrow cells were transferred into the re-
cipients by i.v. injection. At 10 wk after the reconstitution, mice were killed
and lymphocytes were analyzed as indicated.
For the bone marrow reconstitution of FoxP3sf or FoxP3wt Rag-2 / 
mice, all of the mice were given 500 rad irradiation 1 d before reconstitu-
tion, and received 5   106 T cell–depleted bone marrow cells from BALB/c
GFP transgenic mice. 6 wk after the reconstitution, mice were killed and
their thymocytes and splenocytes were analyzed as indicated.
Real-time PCR. Real-time PCR was done using the QuantiTect SYBR
green PCR kit (QIAGEN) in an ABI PRISM 7700 cycler (Applied Biosys-
tems) according to manufacturers’ protocols. In brief, 1  g total RNA was
pretreated with RNase-free DNase I (Invitrogen) to eliminate contaminating
genomic DNA and was reverse transcribed using Superscriptase II (Invitro-
gen) and oligo(dT) in a 20- l reaction. 1  l cDNA was used in each 25- l
PCR reaction, and all samples were run in triplicate. All PCR products were
analyzed by annealing curves as well as 2% agarose gel and contained only one
amplicon with the correct size. The primers were as follows: FoxP3, 5 -
GGCCCTTCTCCAGGACAG-3  and 5 -GCTGATCATGGCTGGGT-
TGT-3 ; ErbB2, 5 -TGAGAAATGCAGCAAGCCCT-3  and 5 -AATGC-
CAGGCTCCCAAAGAT-3 ;  HPRT: 5 -AGCCTAAGATGAGCGCA-
AGT-3  and 5 -TTACTAGGCAGATGGCCACA-3 ;  -actin 5 -GATC-
TGGCACCACACCTTCT-3  and 5 -GGGGTGTTGAAGGTCTCAAA-
3 ; CD4, 5 -TCTGCATCCTCTGTGTC-3  and 5 -GCACTGGCAGGT-
CTTCTTCT-3 ; CD3 zeta chain, 5 -TCTGCTGGATCCCAAACTCT-3 
and 5 -TGCACTCCTGCTGAATTTTG-3 .
Purification of thymic epithelial cells. Thymii from 4–8-wk-old
BALB/c mice were cut into small pieces and stirred for 30 min at 4 C to re-
duce thymocytes. The fragments remaining were digested by 1 mg/ml Col-
lagenase/Dispase (Roche) plus 1 mg/ml Dnase I (Sigma-Aldrich) succes-
sively for three 15-min incubations. Single-cell suspensions went through
the Percoll gradient (1.07, 1.045, 1.03, 1.0), and the upper two layers of
cells were collected. Those cells were stained with CD45.2 APC, and G8.8
(BD Biosciences), followed by FITC-conjugated anti–rat IgG2a (BD Bio-
sciences). Two rounds of FACS sorting were used to purify CD45 G8.8 
thymocytes and CD45 G8.8  epithelial cells.
FACS staining of thymic epithelial cells. Thymus from young adult
mice was digested as described above. Cells from the last two digestions
were combined and incubated with 2.4G2 hybridoma supernatants for 20
min at 4 C to block the FcR. The cells were stained with G8.8 (Rat IgG2a)
and CD45 APC (BD Biosciences) followed by FITC-conjugated anti–rat
IgG2a (BD Biosciences). Excess FTIC anti–rat IgG2a antibody was blocked
by incubating with purified rat IgG for 20 min. Intracellular staining was
conducted using PE-conjugated anti-FoxP3 (FJK-16S) or isotype control as
Figure 7. FoxP3 maintains thymopoiesis by repressing expression of 
ErbB2. Real-time PCR analyses of IL-7 (a) or ErbB2 (b) expression in the WT 
and FoxP3sf thymii at different ages. Data shown are the means   SEM. Day 
7: FoxP3sf, n   5, WT, n   4; Day 15: FoxP3sf, n   3, WT, n   3. (c) Real-time 
PCR analysis of ErbB2 expression in the thymic epithelial cell line 6.1.7 after 
transient transfection of FoxP3 cDNA. The transfectants were selected with 
blasticidin (5  g/ml) to remove untransfected cells. After removing non-
adherent dead cells, mRNA was isolated and quantitated by real-time PCR. 
Data are representative of two independent experiments, using either Hprt 
or  -actin as housekeeping gene. (d) FoxP3 represses Her-2 promoter. Data 
shown are summary of two independent experiments, depicting relative 
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described by the manufacturer (eBioscience). For surface CD4 staining, cells
were incubated with PE-conjugated anti-CD4 (GK1.5, IgG2b) or rat
IgG2b isotype control at 4 C for 30 min.
Transfection. Mouse thymic epithelial cell line 6.1.7 was transfected by
the pcDNA3-FoxP3 or the vector alone using Fugene 6 (Roche). 24 h after
transfection, blasticidin (10  g/ml) was added to deplete the untransfected
cells. 72 h after the selection, cells were harvested and expression of HER-2
was detected by real-time PCR.
Luciferase reporter assay. 104 cells/well of thymic epithelial cells were
seeded in 24-well plates. 0.2  g luciferase construct that contained a 500-bp
ErbB2 promoter and 0.02  g of pRL-TK (Promega) were transiently cotrans-
fected with 0.2  g, 0.5  g, and 1  g  FoxP3 expression plasmid or the
pcDNA3 vector, respectively. After incubation for 48 h, the cells were har-
vested with Passive Lysis Buffer (Promega); luciferase activities of cell extracts
were measured with the use of the Dual Luciferase Assay System (Promega).
Statistical analysis. Unless otherwise noted, most data were analyzed
with two-tailed Student’s t test. *P   0.05, significant; **P   0.01, highly
significant.
Online supplemental material. Fig. S1 shows analysis of thymocyte
apoptosis by annexin V staining. Fig. S2 displays the production and charac-
terization of anti-FOXP3 antibodies. Fig. S3 shows that Her-2 blockade
partially rescues thymopoiesis in scurfy mice. Online supplemental material
is available at http://www.jem.org/cgi/content/full/jem.20050157/DC1.
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